EGFR and non-small cell lung carcinoma: The discovery of key oncogenic events mainly in NSCLC, like epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase rearrangements, have changed dramatically the therapeutic strategy with the introduction of tyrosine kinase inhibitors (TKIs) such as gefitinib (GEF), which regulates tumor progression and metastatic spread attitude with an improvement of symptoms control and patients’ quality of life compared with traditional cytotoxic agents (Maemondo et al., 2010).